<DOC>
	<DOC>NCT02306837</DOC>
	<brief_summary>To imporve the outcome of patients with relapsed/refractory lymphoma, we conduct a clinical trial to test the efficacy and feasibility of consolidation chemotherapy after autologous stem cell transplantation</brief_summary>
	<brief_title>Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies</brief_title>
	<detailed_description>Patients with relapsed or refractory lymphoma will be included. All patients will undergo PBSC mobilization with CTX and G-CSF. After sucessful collection of CD34+ over 1x109/L, autologous stem cel ltransplantation with Bu-Cy-E conditioning will be given. Two months after auto-HSCT, a PET-CT will be performed and all patients with CR, CRu and PR will recieved 3 cycles of mini-Bu-Cy-E as consolidation 3, 6 and 9 months after auto-HSCT. For patients with SD or PD after auto-HSCT will refered to the allogeneic transplantatio program and take off the study.</detailed_description>
	<criteria>Patients with relapsed or refracotry NHL or HD: PR or SD after first line salvage chemotherapy; ECOG: 02 Tbil &lt; 1.5x ULN and AST/ALT &lt;2.5x ULN With informed consent Life expectancy &lt; 3 months Women in pregnancy uncontrollable infection disease serum Cr &gt;400mmol/l uncontroled diabetis and heart disease</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>lymphoma, consolidation chemotherapy, auto-HSCT</keyword>
</DOC>